Alzheimer's: Page 4

Neuroscientists report preliminary validation of Alzheimer’s blood biomarker

By Elissa Wolfson

Brain derived-tau levels detected in Alzheimer’s patients’ blood samples using a new assay matched with tau levels in CSF, reliably distinguishing Alzheimer’s from other diseases.

December 28, 2022

C2N Diagnostics study demonstrates clinical utility of Alzheimer's disease blood test

By LabPulse.com staff writers

The firm said its current PrecivityAD blood test is bolstered by new research that found the test provided clinically informative results in approximately 85% of cases.

December 12, 2022

Roche nabs FDA clearance for two Alzheimer's disease CSF assays

By LabPulse.com staff writers

The assays measure beta Amyloid (1-42) and Phospho Tau (181P) concentrations in cerebrospinal fluid samples from adults age 55 and older.

December 8, 2022

Blood test in study detects proteins fundamental to dementia before symptoms develop

By Maryam Payne

The research team is working with scientists at AltPep, a University of Washington spinout company, to develop a soluble oligomer binding assay as a diagnostic test.

December 5, 2022

Diadem presents data at CTAD on blood test for early prediction of Alzheimer's

By LabPulse.com staff writers

The firm is preparing to launch a test next year that enables drug developers to identify with high confidence individuals who will experience a decline to Alzheimer's dementia up to six years in advance of diagnosis.

December 5, 2022

C2N Diagnostics launching next-generation blood test for Alzheimer's disease detection

By LabPulse.com staff writers

With an anticipated launch in the first quarter of 2023, the PrecivityAD2 blood test would facilitate earlier diagnosis of Alzheimer's disease pathology than is possible with current tests, the firm said.

November 29, 2022

Urine biomarker may reveal early-stage Alzheimer’s disease, study shows

By Maryam Payne

A urine-based test for early Alzheimer’s detection would be inexpensive, noninvasive, widely accessible, and considerably easier to deploy in routine screening than current methods.

November 30, 2022

Blood-based MDx test developer DiamiR to present poster on trial findings at CTAD

By LabPulse.com staff writers

The poster will be presented during the session “Clinical trials: Biomarkers including plasma” during the 15th Clinical Trials on Alzheimer’s Disease (CTAD) in San Francisco from November 29 to December 2.

November 28, 2022

Alzheimer’s study compares blood-based biomarkers, other detection technologies

By Maryam Payne

The Global Alzheimer’s Platform Foundation technology study, with more than 1,000 participants, focuses on access and diversity.

November 15, 2022

NanoMosaic obtains rights to biomarker test for the diagnosis, prognosis of anesthesia-induced delirium, Alzheimer's

By LabPulse.com staff writers

The test uses the Tessie system to alleviate bottlenecks in proteomics analysis and to enable protein interrogation as well as multiomics analysis within a single chip during one run.

October 12, 2022

Diadem nabs $2.5M to further validate Alzheimer’s blood test

By LabPulse.com staff writers

The two-year grant will enable Diadem, a company that has been developing a blood-based test for the early prediction of Alzheimer's disease (AD), to leverage data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a longitudinal multicenter study designed to enable development of biomarkers for the early detection and tracking of AD.

September 6, 2022

Roche nabs FDA breakthrough designation for Alzheimer’s Dx

By LabPulse.com staff writers

The panel, a blood-based biomarker test, is intended to be used in conjunction with other clinical information in symptomatic patients who are being evaluated for Alzheimer's disease and other causes of cognitive decline.

July 18, 2022

Previous Page

Page 4 of 8

Next Page